Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | CBO, CFO, Sec. and Treas. | January 19, 2018 | January 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date January 19, 2018 · Filed January 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.18 · Expires 2028-01-18 | Direct | 131,000 |
Reported balance
After 2018-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-19 · Grant · Acquired 131,000 · Balance 131,000 F1: 25% of the shares subject to the Stock Option will vest and become exercisable on January 19, 2019 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the Stock Option will vest and become exercisable on January 19, 2019 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2018 Filed Jan 23, 2018 16:47 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 131,000 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001209191-18-004916 · doc4.xml · derivative · entry 1 Werber Yaron · CIK 0001704638 · CBO, CFO, Sec. and Treas. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2028-01-18 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on January 19, 2019 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued service through each such date. Read SEC document |
| May 10, 2017 Filed May 10, 2017 17:17 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 93,022 | $0.00 Strike: $8.50 | $0.00 |
DisclosureSEC source: 0001209191-17-031377 · doc4.xml · derivative · entry 1 Werber Yaron · CIK 0001704638 · CBO, CFO, Sec. and Treas. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,022 Underlying: Common Stock · 93,022 shares Expires 2027-01-19 F1 · derivative.exercise_date: 100% of the shares subject to the Stock Option vested and became exercisable upon the closing of the initial public offering resulting in gross proceeds to the Issuer of $75,000,000 in accordance with its terms. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.